Damir Vareslija

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7659914/publications.pdf Version: 2024-02-01

		687363	677142
29	741	13	22
papers	citations	h-index	g-index
31	31	31	1495
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Intrinsic Subtype Switching and Acquired <i>ERBB2</i> / <i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	7.1	135
2	Highly reactive oxygen species: detection, formation, and possible functions. Cellular and Molecular Life Sciences, 2011, 68, 2067-2079.	5.4	133
3	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	6.3	81
4	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.9	51
5	AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells. Clinical Cancer Research, 2012, 18, 3305-3315.	7.0	41
6	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nature Communications, 2022, 13, 514.	12.8	38
7	6-Hydroxydopamine: a far from simple neurotoxin. Journal of Neural Transmission, 2020, 127, 213-230.	2.8	32
8	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
9	Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clinical Cancer Research, 2015, 21, 5371-5379.	7.0	25
10	Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clinical Cancer Research, 2016, 22, 2765-2777.	7.0	23
11	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene, 2018, 37, 2008-2021.	5.9	23
12	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 2020, 15, 2503-2518.	12.0	20
13	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18
14	Patient-Derived Xenografts of Breast Cancer. Methods in Molecular Biology, 2017, 1501, 327-336.	0.9	14
15	A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. Scientific Reports, 2019, 9, 18518.	3.3	14
16	Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 3692-3703.	7.0	13
17	A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552.	6.9	12
18	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene, 2021, 40, 1318-1331.	5.9	10

DAMIR VARESLIJA

#	Article	IF	CITATIONS
19	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. Journal of Molecular Medicine, 2018, 96, 1025-1037.	3.9	9
20	Altered Steroid Milieu in Al-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy. Molecular Cancer Therapeutics, 2019, 18, 1731-1743.	4.1	8
21	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	5.5	8
22	Dexamethasone promotes breast cancer stem cells in obese and not lean mice. Pharmacology Research and Perspectives, 2022, 10, e00923.	2.4	3
23	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.7	Ο
24	Abstract PD13-01: Homologous recombination deficiency represents a new therapeutic strategy for breast cancer brain metastases. , 2021, , .		0
25	Abstract P3-05-24: Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours. , 2015, , .		Ο
26	Abstract P1-07-26: Global analysis of the transcriptome in matched primary and metastatic tumours defines ER specific gene alterations. , 2015, , .		0
27	Abstract P3-05-02: Global characterisation of the SRC-1 transcriptome and rational drug design results in the identification of a novel peptide targeting ADAM22 in endocrine resistance. , 2015, , .		Ο
28	Abstract 861: Global transcription factor repression by the coactivator SRC-1 mediates disease progression in endocrine-resistant breast cancer. , 2016, , .		0
29	Abstract 3557: System-based BCL2 family protein signatures as predictive biomarkers in triple-negative breast cancer. , 2016, , .		0